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Abstract 
    Heme oxygenase-1 (HO-1) is known as a stress-inducible protein. The presesnt 
study is designed to investigate the relationship between HO-1 expression levels and 
clinical features of tongue cancer by using HO-1 responsiveness to stress as a clinical 
indicator. One hundred and twelve biopsy samples from tongue squamous cell 
carcinomas were analyzed 
semiquantitatively by immunohistochemistry. Correlations between the expression level 
of HO-1 and the clinical features of tumors were statistically analyzed. Fifty four 
cases with surgical confirmation 
of lymph node metastasis were examined the association between 
cervical lymph node metastasis (pN) and other clinical features, including the HO-1 
expression level, using logistic regression. The low HO-1 expression group contained 
significantly more undifferentiated samples (P = 0.04) and pN positive cases (P = 0.01) 
by univariate analysis. The low HO-1 expression group (odds ratio = 8.49; 95% 
confidence interval = 1.64-44.09, P = 0.01) and an endophytic shape (odds ratio = 
16.79; 95% confidence interval = 1.77-159.53, P = 0.01) were significantly associated 
with an increased risk of developing lymph node metastasis by multivariate analysis. 
Low HO-1 expression was associated 
with lymph node metastasis. The expression profile suggests HO-1 could be used 
clinically as a 
marker for tumors possessing the potential for lymph node metastasis. This method 
could prove useful as an adjuvant method to detect lymph node metastasis and 
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may help reduce the number of surgeries by indicating when surgery is unnecessary. 
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1. Introduction 
 Heme oxygenase (HO) is originally identified as an enzyme that 
catalyzes the initial reaction in heme catabolism: the oxidative cleavage of the α
-meso carbon bridge of b-type heme molecules to yield equimolar quantities of 
biliverdin IXa, carbon monoxide (CO), and iron. HO has long been 
known to undergo adaptive regulation in response to heme. The effect 
is due to consequence of increased synthesis of a 
32kDa protein, termed HO-1[1]. There are two isoforms: HO-1 and HO-2. HO-2 
is the major isoform that presents under physiological conditions, localized in 
microsomes, and the stress inducible isoform HO-1 is localized in mitochondria. HO-1 
and HO-2 are product of distinct genes. Human HO-1 gene (HMOX1) 
is localized to chromosome 22q12, while HO-2 gene (HMOX2) 
is localized to chromosome 16p13.3. HO-1 is classified as heat-shock protein 
32k (HSP32) [2]. HO-1 expression is very sensitive to stress, and is induced 
by many stimuli, including heme, heavy metal, heat shock, endotoxin, 
inflammatory cytokines, prostaglandins, and oxidative stress. HO-1 is thought to help 
maintain cellular homeostasis [1, 3]. We considered whether we could 
use this characteristic of HO-1 as an indicator of the amount of stress on a cancer. 
There are many reports concerning HSPs, including HSP 27 and 70, and 
associations with clinical findings of squamous cell carcinomas have been shown 
[4-7]. In the head and neck region, HSPs have also been investigated as clinical 
indicators and associations with clinical features have been reported 
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[8-12].  Although there are many reports on HSPs in the head 
and neck region, few are on HO-1. In a previous study the potential of using HO-1 as a 
marker for clinico-pathological features was reported 
[13]. However, the samples consisted of a 
small number from various regions of the head and neck and did not 
include pathological confirmation of cervical lymph node metastasis. Here, we collected 
samples from a uniform region, the tongue, and investigated the relationship 
between HO-1 expression and clinico-pathological features of tongue squamous cell 
carcinoma. We also discuss the usefulness of HO-1 as a clinical indicator 
of lymph node metastasis. 
 
2.Materials and methods 
2.1. Patients 
Tumor specimens were obtained by surgical 
biopsies of the tongue carcinoma from 112 patients who consulted the Division of Head 
and Neck Surgery, Chiba Cancer Center Hospital, during 1975-1999. The median 
age of the patients was 60, 
and the range was 27-88. The male:female ratio was 69:36. The tumors were staged 
according to the International Union Against Cancer (UICC) 
scheme [14]. The composition of the cases is shown in Table 1. 
No treatment for the malignant tumor was performed prior to biopsy. Fifty-four 
cases of the 112 patients underwent neck dissection and pN 
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was determined. The macroscopic shape of the tumors was classified into 4 groups, 
superficial, exophytic, endophytic, and combination type, as described previously [15] 
(Table 1). The maximum diameter was measured clinically. Three patients received 
surgical excision alone, 54 surgical excision and radiotherapy, 
and the remaining 55 patients received radiation therapy alone. For 109 patients treated 
with radiotherapy, 20 received liniac treatment alone (8-76 Gy), 31 received 
interstitial radiation alone (28-70 Gy), 1 electron beam therapy alone (42 Gy), and 57 a 
combination of these radiation therapies (10-85 Gy + 48.6-83 Gy).  
 
2.2. Methods 
Immunostaining was performed using the horseradish peroxidase-labeled 
streptavidin and biotin technique as described previously [13]. The samples were fixed 
with 10% neutral formalin buffered fixed specimens were embedded in paraffin and cut 
5μm. The polyclonal antibody (Affinity Bioreagents, Inc, Golden, USA) was diluted 
1:50 v/v in PBS, and the slides were incubated in the antibody solution 
at room temperature for 1 hour. The slides were reacted with biotinylated goat 
anti- rabbit IgG antibody, followed by horseradish peroxidase-conjugated streptavidin, 
and visualized with 3,3’-diaminobenzidine. One pathologist who was not informed 
of the patient’s clinical status examined the immunostained slides. 
The HO-1 immunostaining was semiquantified by a visual grading system in 
which the intensity of staining was categorized as Grade 0, 1+, 2+, or 3+, 
similar to a previously reported system [13]. Grade 0 was defined as the total 
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absence of HO-1 I immunostaining (Fig. 1A); Grade 1+ as < 25% of the tumor 
staining positive, or only faint staining (Fig. 1B); Grade 2+ as 25-50% of the tumor 
staining positive (Fig. 1C); and Grade 3+ as > 50% of the tumor staining positive (Fig. 
1D).  
For univariate analysis we used Student’s t-test, Fisher’s exact probability test, 
and the chi-square test. For multivariate analysis, multiple logistic regression 
analysis was used. The analyses were performed using the statistical 
software package StatView 5.0 (SAS Institute Inc. Cary, NC, USA.). 
 
3. Results 
 
3.1. Correlation between HO-1 expression and clinico-pathological features 
HO-1 immunostaining of the tumor was classified into Grade 0, 10.7% (12 of 
112); Grade 1+, 42.9% (48 of 112); Grade 2+, 27.7% (31 of 112); and Grade 3+, 18.8% 
(21 of 112). To simplify the correlation of HO-1 expression with 
clinical features, these groups were reclassified into low- (Grade 0, Grade 1+) and high- 
(Grade 2+, Grade 3+) HO-1 -expression groups. In 
addition, the T-categories were divided into T1 + T2 and T3 + T4 groups, and the N 
and pN-categories for lymph node metastasis as negative (N0) 
and lymph-node positive (N1 + 2) groups. The clinical stages were in addtion grouped 
into stage I + II and stage III + IV. The differentiation categories were divided 
into moderately or poorly differentiated (G2 + G3) and well differentiated (G1). 
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Table 2 shows the correlation between the HO-1 expression level 
and the clinico-pathological features of these cases. Comparison of the expression level 
of HO-1 with clinico-pathological features showed that high-expression groups included 
significantly more differentiated tumor cases. There were significant 
differences in the expression level of HO-1 between the G2 + G3 and G1 groups (P = 
0.04), and between the pN0 and pN1 + 2 groups (P = 0.01). No significant 
difference in HO-1 expression was observed with respect to other factors, such as age, 
sex, T category, N category, stage, macroscopic shape, and maximum diameter. 
 
3.2. Correlation between pN and clinico-pathological features including HO-1 
expression 
We then focused on the pN result and evaluated whether the HO-1 expression level 
could be a useful predictor of lymph node metastasis. The relationship between pN (N0 
or N1 + 2) and clinico-pathological features was investigated 
by univariate analysis (Table 3). To simplify the classification, 
we divided the macroscopic shape classification 
into two groups, the endophytic type and the other types. To exclude the influence of 
irradiation, the irradiation type was used as a variable, 
dividing the cases into the following two groups: irradiation 
of the neck (the cases involving liniac irradiation) and cases without neck irradiation 
(the other cases, involving the interstitial therapy, no irradiation, 
etc.). This analysis showed that endophytic type (P = 0.03) and low HO-1 
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expression level (P = 0.01) were significantly associated with positive lymph nodes. 
Subsequently multivariate analysis was used. The predictor variables in 54 
cases were used in a logistic regression model with negative or positive pN 
as the dependant variables. A logistic model for predicting pN was constructed 
using clinical variables, including age, sex, T or N category, stage, differentiation, with 
or without neck irradiation, maximum diameter, macroscopic shape, and HO-1 
expression level. The adjusted odds ratios (OR) and 95% confidence intervals (CI) 
are shown 
in Table 4. The pathologically positive lymph nodes were significantly associated with 
an 8.49-fold increase in the low expression of HO-1 (OR = 8.49; 95% CI = 1.64-44.09, 
P = 0.01) and a 16.79-fold increase in the endophytic type (OR = 16.79; 95% CI = 
1.77-159.53, P=0.01), but the other predictors were not significantly associated with pN. 
 
4. Discussion 
In the present study we found HO-1 expression in 112 cases of tongue SCC 
was associated with pN (P = 0.01) and differentiation (P = 0.04) by univariate analysis. 
We also found pN was significantly associated with HO-1 expression level (P = 0.01) 
and endophytic type (P = 0.01) 
by multivariate analysis. It has previously been found that the low-HO-1 expression 
group was correlated with N category and poor differentiation 
[13]. Here, the results of the differentiation 
are similar to those of the previous report. The correlation between pN and macroscopic 
 12
shape are also in agreement [15]. However, in the present study no correlation 
with the N category was found. This discrepancy may be due to a 
difference in the diagnostic methods, which have improved since 1970s, 
and the fact that the accuracy of determining the N category in the older cases was not 
as good as for recent cases. However, pN, which is a more accurate method for 
defining whether lymph node metastasis exists, correlated with HO-1 expression. 
The reason the HO-1 expression level was associated 
with lymph node metastasis is still uncertain. However, following hypothesis could 
be suggested. One is the stress response of tumors against the immune recognition 
of the host. If a tumor suffers from stress caused by the human body, this finding, which 
suggests that metastasis is more difficult for the stressed cancer cell, 
is reasonable. HO-1 is a very sensitive stress-inducible protein that is up-regulated 
by very small stressors [1]. If the human immune system recognizes the tumor cell 
as a nonself antigen, tumor cells will be attacked by the defense system of the host, 
making metastasis to the peripheral regions difficult. To the contrary, however, 
grafts that had induced HO-1 expression survived rejection better than grafts that 
did not have elevated HO-1 expression [16, 17]. This may mean that cells that 
are rejected by the human body endure under stressful 
conditions by expressing stress proteins like HO-1, but that that there is no additional 
benefit to expressing stress-responsive gene products for cells that can 
easily escape from immune recognition. 
Another possibility is genetic disturbance. The heme oxygenase gene is located in 
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22q12 of the human chromosome [18, 19]. There are interesting reports that indicate an 
association between allelic loss on chromosome 22 and 
clinico-pathological features in head and neck squamous cell carcinoma [20, 
21].  If there is some genetic factor, like a tumor suppressor gene, that 
suppress carcinogenesis and invasiveness of the tumor near 22q, this could 
explain the coincidence between the loss of HO-1 expression 
and lymph node metastasis.   
The control of cervical lymph node metastasis is a crucial factor for 
good prognosis in head and neck cancer treatment. In practice, computed tomography, 
magnetic resonance imaging, and ultrasonography are very useful for 
detecting lymph node metastases. Such methods are characterized by the morphological 
aspect for diagnosis and do not reflect the characteristics of the tumor 
biology. Furthermore, very small lymph nodes, i.e., less than 5 mm in diameter, cannot 
be identified using these imaging techniques [22]. In addition, 
although there are many indicators associated with the cell cycle, apoptosis, 
growth factors, cell adhesion, etc., that are correlated with prognosis or 
clinicopathological features [23, 24], the use of HO-1 expression is novel, 
and there are only a few reports of markers that indicate lymph node metastasis. If 
we can use this property of HO-1 expression to predict 
cervical lymph node metastasis clinically, it may prove helpful as an adjuvant 
method to detect lymph node metastasis and may help reduce the number of 
surgeries, like elective neck dissection, by indicating when such surgery is unnecessary.  
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Figure legend 
 
Fig. 1. Representative photomicrographs of immunohistochemical staining with HO-1 
antibody according to the visual grading system. Grade 0 (a total absence of HO-1 I 
immunostaining) (A), Grade 1+ (< 25% of tumor staining positive) (B), Grade 2+ 
(25-50%) (C), Grade 3+ (> 50%) (D). (original magnification, x100)  
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YANAGAWA
TABLE 1
Clinical features
Median age 60
Range 27-88
Sex ratio f/m 36 /76
Macroscopic shape
Exophytic 20
Combination 26
Endophytic 45
Superficial 21
Maximum diamater
of tumor
Mean±S.D. 3.19±1.47
Radiation
Liniac 20
Interstitial therapy 31
Electron therapy 1
No irradiation 3
Liniac+other radiation therapies 57
Surgery
Without surgery 55
Excision with neck dissection 54
Excision alone 3
TNM classification n
T category T1 32
T2 47
T3 26
T4 7
N category N0 78
N1 14
N2a 3
N2b 12
N2c 5
M category M0 111
M1 1
Stage Stage I 33
Stage II 33
Stage III 22
Stage IV 24
pN N0 19
N1 11
N2a 3
N2b 17
N2c 4
Characteristics for Oral Squamous Cell Carcinoma
Case Patients

TABLE 2
High
Expression
Low
Expression P value
Age
>60 28 31 0.82 c
60>= 24 29
Sex
Female 13 23 0.13 c
Male 39 37
T category
T1+2 41 38 0.07 c
T3+4 11 22
N category
N0 39 38 0.18 c
N1+2 13 22
Stage
I+II 34 32 0.20 c
III+IV 18 28
Differentiation
Moderately or poorly 15 29 0.04 c
Well 37 31
Macroscopic shape
Exophytic 8 12 0.68 c
Combination 14 12
Endophytic 19 26
Superficial 11 10
Maximum diamater
of tumor (n) 52 60
Mean±S.D. 3.09±1.44 3.28±1.50 0.75 t
pN
pN0 13 6 0.01 c
pN1+2 11 24
F: Fisher's exact test
t: Student's t-test
Correlation with HO-1 Expression and Clinicopathological Features
c: chi square test

TABLE 3
pN negative pN positive P value
Age
>60 9 18 0.78 c
60>= 10 17
Sex
Fmale 5 10 0.86 c
Male 14 25
T category
T1+2 13 23 0.84 c
T3+4 6 12
N category
N0 12 17 0.30 c
N1+2 7 18
Stage
I+II 10 15 0.49 c
III+IV 9 20
Differentiation
G2+3 8 22 0.14 c
G1 11 13
Macroscopic shape
Endophytic 4 18 0.03 F
Other 15 17
Maximum diamater of
tumor 19 35
3.17±1.30 3.28±1.67 0.24 t
HO-1 expression
High 13 11 0.01 c
Low 6 24
Radiation
With neck irradiation 14 27 0.78 c
Without neck irradiation 5 8
Correlation with pN and Clinicopathological Features including HO-1 expression
c: chi square test
F: Fisher's exact test
t: Student's t-test

TABLE 
Adjusted OR 95% CI P value
Age (60:60) 1.34 0.24-7.37 0.74
Sex (female :  male) 0.53 0.09-3.36 0.50
T category (T1+2: T3+4) 0.28 0.02-4.62 0.37
N category (negative :
positive) 3.61 0.20-64.17 0.38
Stage ( I+II : III+IV) 0.28 0.02-17.77 0.80
Differentiation (G2+3 : G1) 0.61 0.13-2.86 0.53
Radiation (with  : without
neck irradiation) 0.74 0.11-4.89 0.75
Macroscopic shape ( the
others : endophytic type) 16.79 1.77-159.53 0.01
Maximum diamater of tumor 0.86 0.35-2.12 0.74
HO-1 expression (high : low) 8.49 1.64-44.09 0.01
 Odds ratios (OR) and 95% Confidence Intervals (CI) for pN-positive
cases associated with clinicopathological features including HO-1
expression

